Background: Prevention campaigns for skin cancers have focused primarily on melanoma, and over time there has been increasing awareness of the need to select the population to be screened to maximize program effectiveness. Objectives: The objective of the study was to report the results of a free dermatological initiative, as part of an awareness campaign dedicated to keratinocyte cancers, targeting individuals pre-selected through a short questionnaire. Methods: One day of dermatological consultations was held at 15 dermato-oncology referral centers during May 22–June 30, 2021. For selection, individuals answered a telephone interview consisting of 7 yes/no questions on risk factors. Demographics, clinical characteristics of suspicious tumors, and histopathologic diagnosis of excised lesions were collected. Suspicion rate, detection rate, and positive predictive values (PPVs) for any skin cancer, basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (cSCC), and melanoma were calculated. Results: A total of 320 individuals (56.9% males; 43.1% females) with a median age of 69.6 (range 21–91) years qualified for the screening initiative. Overall, skin cancers and precancerous lesions were diagnosed in 65.9% of the patients. Suspicion rate was 28.7% for any skin cancer (92/320), 22.8% for BCC (73/320), 4.7% for cSCC (15/320), and 1.2% for melanoma (4/320). Detection rate was 23.4% for any skin cancer (PPV 93.7%), 18.1% for BCC (PPV 95.1%), 4.4% for cSCC (PPV 93.3%), and 0.9% for melanoma (PPV 75%). Conclusions: Selection of individuals at high risk is a cost-effective approach for early detection campaigns for keratinocyte cancers.

Keywords:
Awareness campaign, Early detection, Dermatological consultation, Keratinocyte cancers, Prevention, Cutaneous squamous cell carcinoma, Basal cell carcinoma, Actinic keratosis, Nonmelanoma skin cancers
1.
Green AC, Olsen CM. Cutaneous squamous cell carcinoma: an epidemiological review. Br J Dermatol. 2017 Aug;177(2):373–81.
2.
Garbe C, Keim U, Gandini S, Amaral T, Katalinic A, Hollezcek B, et al. Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943-2036. Eur J Cancer. 2021 Jul;152:18–25.
3.
Global Burden of Disease 2019 Cancer Collaboration, Kocarnik JM, Compton K, Dean FE, Fu W, Gaw BL, Harvey JD, et al. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the global burden of disease study 2019. JAMA Oncol. 2022 Mar 1;8(3):420–44.
4.
Peris K, Fargnoli MC, Garbe C, Kaufmann R, Bastholt L, Seguin NB, et al. Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines. Eur J Cancer. 2019 Sep;118:10–34.
5.
Brancaccio G, Briatico G, Pellegrini C, Rocco T, Moscarella E, Fargnoli MC. Risk factors and diagnosis of advanced cutaneous squamous cell carcinoma. Dermatol Pract Concept. 2021 Sep 1;11(Suppl 2):e2021166S.
6.
Brantsch KD, Meisner C, Schönfisch B, Trilling B, Wehner-Caroli J, Röcken M, et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol. 2008 Aug;9(8):713–20.
7.
Schmults CD, Karia PS, Carter JB, Han J, Qureshi AA. Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study. JAMA Dermatol. 2013 May;149(5):541–7.
8.
Wolff T, Tai E, Miller T. Screening for skin cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2009 Feb 3;150(3):194–8.
9.
Wernli KJ, Henrikson NB, Morrison CC, Nguyen M, Pocobelli G, Whitlock EP. Screening for skin cancer in adults: an updated systematic evidence review for the U.S. Preventive services task force. Rockville (MD): Agency for Healthcare Research and Quality (US); 2016 Jul.
10.
Brunssen A, Waldmann A, Eisemann N, Katalinic A. Impact of skin cancer screening and secondary prevention campaigns on skin cancer incidence and mortality: a systematic review. J Am Acad Dermatol. 2017 Jan;76(1):129–39.e10.
11.
Krensel M, Andrees V, Mohr N, Hischke S. Costs of routine skin cancer screening in Germany: a claims data analysis. Clin Exp Dermatol. 2021 Jul;46(5):842–50.
12.
Gordon LG, Rowell D. Health system costs of skin cancer and cost-effectiveness of skin cancer prevention and screening: a systematic review. Eur J Cancer Prev. 2015 Mar;24(2):141–9.
13.
Choudhury K, Volkmer B, Greinert R, Christophers E, Breitbart EW. Effectiveness of skin cancer screening programmes. Br J Dermatol. 2012 Aug;167(Suppl 2):94–8.
14.
Mylle S, Verhaeghe E, Van Coile L, Van de Maele B, Hoorens I, Brochez L. Lesion-directed screening to optimize skin cancer detection in dermatology practice: an observational study. J Eur Acad Dermatol Venereol. 2021 Jun;35(6):1309–14.
15.
Suppa M, Altomare G, Cannavò SP, Capizzi R, Catricalà C, Colombo E, et al. The Italian Euromelanoma Day: evaluation of results and implications for future prevention campaigns. Int J Dermatol. 2014 Jun;53(6):699–706.
16.
Breitbart EW, Waldmann A, Nolte S, Capellaro M, Greinert R, Volkmer B, et al. Systematic skin cancer screening in Northern Germany. J Am Acad Dermatol. 2012 Feb;66(2):201–11.
17.
Seidenari S, Benati E, Ponti G, Borsari S, Ferrari C, Albertini G, et al. Italian Euromelanoma Day Screening Campaign (2005-2007) and the planning of melanoma screening strategies. Eur J Cancer Prev. 2012 Jan;21(1):89–95.
18.
Dubbini N, Puddu A, Salimbeni G, Malloggi S, Gandini D, Massei P, et al. Melanoma prevention: comparison of different screening methods for the selection of a high risk population. Int J Environ Res Public Health. 2021 Feb 17;18(4):1953.
© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.